Real-world patient profile and step-up dosing process of early initiators of teclistamab for multiple myeloma in US hospitals: An analysis using the Premier Healthcare Database
This large, national, real-world study of patients with MM treated with teclistamab confirmed that early initiators of teclistamab were older adults from diverse racial groups with substantial comorbidities. Despite these factors, most patients were able to safely complete SUD following label-described schedules with manageable CRS events.
Authors
- Bingcao Wu (ORCID: https://orcid.org/0000-0002-7027-8062)
- Jessica Fowler (ORCID: https://orcid.org/0000-0002-1796-0513)
- Dina Gifkins (ORCID: https://orcid.org/0000-0002-5645-6213)
- Nina Kim (ORCID: https://orcid.org/0000-0002-1809-0417)
- Eric Chinaeke (ORCID: https://orcid.org/0000-0002-8287-0012)
- Dee Lin (ORCID: https://orcid.org/0000-0003-2565-7984)
- Alex Z. Fu (ORCID: https://orcid.org/0000-0002-4020-6519)
- Laura Hester (ORCID: https://orcid.org/0000-0002-4593-1293)
- Carlyn Rose C. Tan (ORCID: https://orcid.org/0000-0001-7922-2594)
- Sian Walker
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Janssen (Belgium) (BE)
- Georgetown University (US)
- Georgetown University Medical Center (US)
- Tahoe Forest Hospital (US)
- Janssen (United States) (US)
- Janssen Scientific Affairs (United States)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2025-07-24
- DOI
- https://doi.org/10.18553/jmcp.2025.31.8.772
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00